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ABSTRACT
Introduction: Severe eosinophilic asthma is an incapacitating disease. Mepolizumab, a
humanized anti-interleukin-5 monoclonal antibody, proved to be effective as an add-on
therapy in patients with severe eosinophilic asthma. However, only data from randomized
controlled trials are available and real world data are lacking.
Methods: A retrospective observational longitudinal study was conducted in a real world
cohort of patients with severe eosinophilic asthma treated with mepolizumab. The primary
objective was to determine response rate, based on a global evaluation of treatment effect-
iveness by the treating pulmonologist. Secondary objectives were to assess exacerbation fre-
quency, systemic maintenance glucocorticoid usage, Asthma Control Questionnaire (ACQ),
lung function, and adverse events.
Results: Seventy-eight patients were included. Treatment with mepolizumab was considered
beneficial and was therefore continued in 75.6% of patients 12months from the initiation of
mepolizumab. The most common reason for drop-out was insufficient response. Secondary
objectives: 12months from the initiation of mepolizumab there was a decrease of 3.2 (CI
2.5–4.1; p< 0.001) severe asthma exacerbations per year, a decrease of ACQ of 0.80 points
(CI 0.49–1.12; p< 0.001), and an increase of 3.7 (CI 0.3–7.2; p¼ 0.034) percent of predicted
FEV1 compared to baseline. At baseline 51.3% of patients were treated with systemic gluco-
corticoid maintenance therapy, compared to 15.4% (p< 0.001) of patients 12months from
the initiation of mepolizumab. No serious adverse events considered to be related to mepo-
lizumab were reported.
Conclusion: This study confirms that mepolizumab add-on therapy is effective and safe in a
real world cohort of patients with severe eosinophilic asthma.
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Introduction
Asthma is a heterogeneous inflammatory airway dis-
ease with symptoms varying over time and in inten-
sity (1). In most cases, asthma can be well treated
with a combination of inhaled glucocorticoids and a
bronchodilator (1). However, 17 and 3.7% of patients
with asthma suffer from difficult to treat asthma or
severe asthma, respectively (2). Severe asthma is a
subset of difficult-to-treat asthma, defined as asthma
which requires treatment with high dose inhaled corti-
costeroids plus a second controller [and/or mainten-
ance systemic corticosteroids (mOCS)] to prevent it
from becoming uncontrolled or which remains uncon-
trolled despite this therapy (3). Patients with severe
asthma experience a heavy burden of symptoms, exac-
erbations, and medication side effects leading to a
decreased quality of life and considerable psychosocial
impact (1,4,5). Additionally, severe asthma has a sig-
nificant economic impact on society. The total costs
(direct, indirect, and intangible) are difficult to esti-
mate, but the treatment costs alone are estimated to
be £2912–£4217 (e3413–e4943) per person per year
(6). Therefore, optimal treatment to control severe
asthma is important.
Severe asthma is a heterogenic disease with several
phenotypes, such as early onset atopic asthma, late
onset eosinophilic asthma, neutrophilic asthma, and
late onset obese asthma. Eosinophilic asthma accounts
for 55% of severe asthma cases (7). Severe eosinophilic
asthma is mostly late onset, characterized by frequent
exacerbations and may only be controlled using main-
tenance systemic corticosteroids (mOCS). Persistent
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blood eosinophilia (an eosinophilic cell count of
>0.30 109/L when on high dose inhaled glucocorti-
coids or >0.15  109/L when on mOCS) is a hallmark
of this phenotype.
Mepolizumab is a humanized monoclonal antibody
that binds to and inactivates interleukin-5 and effect-
ively inhibits eosinophilic airway inflammation (8).
Three randomized controlled trials (RCTs) showed
clinical efficacy of mepolizumab 100mg subcutane-
ously as add-on treatment in patients with severe
refractory eosinophilic asthma (9–11). Therefore,
mepolizumab is approved and registered in The
Netherlands as add-on medication for patients with
severe refractory eosinophilic asthma since February
2016. As it is important to assess effectiveness and
safety of novel treatments in real world practice,
Dutch healthcare authorities and health insurance
companies require healthcare professionals to collect
data regarding mepolizumab efficacy and safety in
clinical practice. This observational single center study
was conducted to evaluate response rate, effectiveness,
and safety in real world practice.
Methods
Study design
The MepOlizuMab Experience in the NeTherlands
(MOMENT) study is a retrospective observational,
longitudinal study in patients with severe eosinophilic
asthma treated with mepolizumab in a tertiary referral
center for severe asthma in Rotterdam, The
Netherlands. Approval of the local Medical Ethics
Committee was obtained.
From August 2018 until April 2019 patients
18 years or older, with severe eosinophilic asthma and
who were treated with at least one dose of mepolizumab
were randomly asked to participate in the study. All
included patients provided written informed consent.
Patients with COPD (Chronic Obstructive Pulmonary
Disease) or EGPA (Eosinophilic Granulomatosis with
PolyAngiitis) were excluded. Mepolizumab was adminis-
tered every 4weeks with a dose of 100mg subcutaneously.
Data were collected by the first two authors and
randomly cross-checked, using Castor EDC (Castor
Electronic Data Capture, Ciwit BV, Amsterdam, The
Netherlands 2018).
Data were collected retrospectively 12months
before the initiation of mepolizumab, at the start of
mepolizumab (baseline) and 2, 4, 6, 9, and 12months
from the initiation of mepolizumab. The personal data
were anonymized and handled according to the
General Data Protection Regulation.
Objectives and statistics
Demographic and other baseline characteristics were
summarized using descriptive statistics.
Primary objective
The primary objective was to determine the response
rate and (dis)continuation rate of mepolizumab, based
on a global evaluation of the treatment effectiveness
by the treating pulmonologist. Additionally, the
reasons for discontinuation of mepolizumab were
assessed.
Secondary objectives
A binominal logistic regression was performed to
assess the effects of type of asthma (allergic eosino-
philic versus non allergic eosinophilic asthma), eosino-
phil count, smoking behavior, and mOCS usage on
the likelihood that mepolizumab was discontinued
12months from baseline. These independent variables
were used because these can theoretically influence
the effect of mepolizumab: possibly not only eosino-
philic inflammation, but also other pathways play an
important role in the severity of allergic eosinophilic
asthma resulting in a reduced effect of mepolizu-
mab (12); an earlier study showed a close relation-
ship between baseline blood eosinophil count and the
effect of mepolizumab on exacerbation frequency (13);
smoking reduces pulmonary eosinophil numbers
and IL-5 concentrations which could reduce the
effect of mepolizumab (14); patients with steroid
resistant asthma may have a different immunophe-
notype compared to patients with steroid sensitive
asthma (15).
The effects of mepolizumab on exacerbation rate,
steroid-sparing effect, Asthma Control Questionnaire
(ACQ-6) and lung function were analyzed in order to
compare the effectiveness of mepolizumab in real
world practice with the effectiveness reported in
RCTs. The hypothesis is that the effectiveness in real
world practice is similar to the effectiveness in RCTs.
The effect of mepolizumab on asthma exacerba-
tions was evaluated by calculating the difference in
the mean frequency of severe asthma exacerbations
and hospitalizations due to asthma exacerbations prior
and during treatment with mepolizumab. The null
hypothesis that there was no difference in the mean
frequencies prior and during treatment with mepoli-
zumab was tested by paired samples t-test. Severe
asthma exacerbations were defined as any severe peak
of symptoms that required an increase in dose of
mOCS for three days or more, a cycle of systemic cor-
ticosteroids, a visit to the emergency department,
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hospitalization, mechanical ventilation, or intensive
care unit admission.
The steroid-sparing effect of mepolizumab was
evaluated by comparing the percentage of patients
being treated with mOCS before, 6months from and
12months from the initiation of mepolizumab. The
null hypothesis that there was no difference in the
percentage of patients treated with mOCS at baseline
compared to 6 and 12months from the initiation of
mepolizumab was tested by McNemar’s test.
To evaluate the effect of mepolizumab on ACQ
and lung function the mean ACQ, mean percent of
predicted FEV1 post bronchodilation and mean FeNO
before, 6months from and 12months from the initi-
ation of mepolizumab were compared. The null
hypothesis that there was no difference in the mean
ACQ, mean percent of predicted FEV1 and mean
FeNO at baseline compared to 6 and 12months from
the initiation of mepolizumab was tested by paired
samples t-test. An improvement in ACQ of 0.5 or
more was considered clinically relevant.
As there were some missing values in the data of
ACQ and lung function (in particular FeNO), only
patients without missing data were included when cal-
culating a difference between two time points and
when testing the null hypothesis.
Data of all adverse events were collected and
reported in this study in order to comply with
European pharmacovigilance regulations. Adverse
events were also reported to Lareb, the national
authority collecting and analyzing data regarding
adverse events.
Results
Patients
A total of 78 patients with severe eosinophilic asthma
were included in our study. The mean age was
54 years, 54% was female, most patients had late onset
non allergic asthma, the mean rate of severe exacerba-
tions per year was 4.6, and 51.3% of patients used
mOCS. Table 1 shows the characteristics of the
patients at baseline. The most common comorbidities
were rhinosinusitis and nasal polyposis. Table 2 shows
the comorbidities of the included patients at baseline.
Table 1. Characteristics of the patients at baseline.
Type of asthma—no. (%)a
Allergic 34 (43.6)
Non allergic 44 (56.4)
Onset of asthma—no. (%)
Early onset 25 (32.1)
Late onset 42 (53.8)
Unknown 11 (14.1)
Mean age—years (range) 54 (20–83)
Female gender—no. (%) 54 (69.2)
Ethnicity—no. (%)
Caucasian 67 (85.9)
Other/Mixed 8 (10.3)
African origin 3 (3.8)
BMI—median (range) 28.4 (20.9–57.7)
Patients with obesity—no. (%)b 31 (39.7)
Smoking—no. (%)
Never 51 (65.4)
Former 25 (32.1)
Smoker 2 (2.6)
Glucocorticoid use—no. (%) 40 (51.3)
Daily glucocorticoid dose—median mg prednisolone equivalent (range)c 10 (3–50)
History of treatment with omalizumab—no. (%) 18 (23.1)
Severe exacerbations in previous year—mean no./patient (range) 4.6 (0–12)
Hospitalization due to an exacerbation in previous year—no. (%) 26 (33.3)
Intubation due to an exacerbation in previous year—no. (%) 2 (2.6)
ACQ score—mean (SD) 2.56 (±0.96)
FEV1 post bronchodilation—mean percent of predicted value (SD)d 75.9 (±17.3)
FEV1:FVC ratio post bronchodilation—mean percent (SD) 66.3 (±11.9)
FeNO—mean ppb (SD) 53.3 (±39.8)
Blood eosinophil count—median 109/L (IQR)e 0.40 (0.20–0.67)
aThe diagnosis allergic asthma was based on a history of symptoms that occur upon exposure to a particular aeroallergen, or persist-
ent symptoms and suspicion of exposure to a relevant allergen in the (home) environment, and the presence of specific IgE anti-
bodies to the inhalant allergen.
bObesity is defined as a Body Mass Index (BMI) of 30 kg/m2 or more.
cMedian daily glucocorticoid dose of the patients being treated with maintenance systemic glucocorticoids.
dPredicted values were acquired using the Global Lung Function Initiative (GLI) prediction equations.
eIn some patients, blood eosinophil count was measured during maintenance glucocorticoid treatment.
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Response rate
Mepolizumab therapy was considered successful and
was therefore continued in 66 (84.6%) and 59 (75.6%)
patients 6 and 12months from the start of treatment,
respectively. The reason for discontinuing mepolizu-
mab was insufficient response in 14 (17.9%) patients.
In 4 (5.1%) patients the combination of insufficient
response and adverse events (an increase in allergic
symptoms in two patients, fever in one patient, low
back pain and malaise in 1 patient) was the reason for
ceasing mepolizumab therapy. One (1.3%) patient had
abdominal pain due to an Entamoeba histolytica and
Helicobacter pylori infection 6months from the start
of mepolizumab therapy upon which mepolizumab
was stopped temporarily. After successful treatment of
the infection the patient preferred continuing mOCS
over mepolizumab, which led to definitive discontinu-
ation of mepolizumab in this patient.
Of the 19 patients that discontinued mepolizumab,
17 (89.5%) proceeded treatment with another bio-
logical agent (10 patients reslizumab, 4 benralizumab,
2 dupilumab, 1 omalizumab) after discontinuing
mepolizumab treatment.
Risk factors for discontinuation
Patients with nonallergic asthma were 3.3 times (CI
1.1–10.4; p¼ 0.042) less likely to have stopped mepolizu-
mab therapy 12months from baseline compared to
patients with allergic asthma. The other variables did not
show a statistically significant effect on this outcome.
Asthma exacerbations
The mean rate of severe asthma exacerbations was 4.6
(range 0–12) during the year prior to the start of
mepolizumab. During mepolizumab therapy, this rate
was 1.4 per patient year (range 0–6). This is a
decrease of 3.2 (CI 2.5–4.1; p< 0.001) severe exacerba-
tions per patient year compared to the number of
severe exacerbations in the year prior to mepolizumab
treatment. The mean number of hospital admissions
due to an asthma exacerbation was 0.35 per patient
year (range 0–5) during treatment with mepolizumab
compared to 0.77 (range 0–10) during the year prior
to mepolizumab treatment, this is a mean difference
of 0.42 (CI 0.17–0.68; p¼ 0.001). There were no
patients requiring intubation due to an asthma exacer-
bation during mepolizumab treatment.
Systemic glucocorticoid maintenance therapy
At baseline, 40 (51.3%) patients were treated with
mOCS. At 6months from baseline 24.3% (compared
to baseline p< 0.001) of the patients still being treated
with mepolizumab were on mOCS. This percentage
was 15.4% (compared to baseline p< 0.001) 12months
from baseline.
ACQ
The mean ACQ at baseline was 2.56 (SD ±0.96). At
6months from baseline the ACQ of the patients still
using mepolizumab decreased 0.84 points (CI 0.61-
1.07; p< 0.001). At 12months from baseline, the ACQ
was 0.80 points lower compared to baseline (CI
0.49–1.12; p< 0.001).
Lung function
The mean percent of predicted FEV1 post broncho-
dilation (SD) was 75.9 (±17.3) at baseline. The mean
absolute increase of the percentage of predicted FEV1
was 2.7 (CI 0.6 to 5.9; p¼ 0.109) 6months from
baseline. At 12months from baseline, this change was
3.7 (CI 0.3–7.2; p¼ 0.034)% of predictive value.
The mean FeNO (SD) was 53.3 (±39.8) ppb at
baseline. The FeNO decreased 8.5 ppb (CI 22.6 to
5.6; p¼ 0.231) and 6.7 ppb (CI 20 to 6.7; p¼ 0.318)
6 and 12months from baseline, respectively.
Adverse events
Adverse events were reported by 37 patients (47.4%).
Adverse events that occurred in at least 2 (2.6%)
patients are listed in Table 3. Data of all adverse
events are provided in Appendix Table A1. Headache
was the most frequently reported adverse event. In
Table 2. Comorbidities of the patients at baseline.
Comorbidity no. (%)
Rhinosinusitis 38 (48.7)
Nasal polyposis 24 (30.8)
Obstructive sleep apnea syndrome 12 (15.4)
Diabetes mellitus 9 (11.5)
Cardiovascular disease 7 (9.0)
Bronchiectasis 7 (9.0)
Depressive disorder 7 (9.0)
Frequent exacerbations requiring antibiotics 6 (7.7)
Gastroesophageal reflux disease 6 (7.7)
Malignancya 4 (5.1)
Complications due to glucocorticoid therapy—no. (%)b 5 (6.4)
aTwo patients had localized breast cancer more than 5 years ago. One
patient had localized bladder cancer (transitional cell carcinoma) more
than 5 years ago. One patient had an inverted papilloma of the nose.
bDiseases that were considered most likely due to glucocorticoid therapy:
one patient had a psychosis, one patient adrenal insufficiency, one
patient cataract, one patient liver function disorders due to a metabolic
syndrome and one patient an avascular necrosis.
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most patients, the onset of headache was shortly after
the first dose of mepolizumab. The headache resolved
in all patients during the first 6months from baseline.
No serious adverse events considered to be related to
mepolizumab were reported during our study.
Discussion
Several RCTs demonstrated a beneficial effect of
mepolizumab add-on therapy in patients with severe
eosinophilic asthma (9–11). However, little is known
about the response rate, efficacy, and safety of mepoli-
zumab in daily practice. To our knowledge, our study
is the largest study to date to assess response rate, effi-
cacy as well as safety in patients with severe eosino-
philic asthma who are treated with at least one dose
of mepolizumab.
In our study 75.6% of patients continued mepolizu-
mab therapy 1 year from the initiation of mepolizu-
mab. The main reason for discontinuation of
mepolizumab was insufficient response based on glo-
bal evaluation of treatment effect. Other reasons were
the combination of insufficient response and adverse
events, and patient’s decision. The mean drop-out rate
in RCTs was 9% with a mean treatment duration of
8.5months (16). Reasons for drop-out in RCTs were
“other” (not specified; 36.5% of the patients that
dropped out), adverse events (23.7%), lack of efficacy
(21.3%), and personal decision (19.5%) (16). To our
knowledge, three real world studies assessed drop-out
rate (studies only including responders (patients
treated with mepolizumab for at least 12months)
were excluded): Zhang et al. (17) reported a drop-out
rate of 20% in 30 patients with a mean treatment dur-
ation of 5.4months. Drop-out was due to insufficient
response (50%) and adverse events (50%). Lombardi
et al. (16) reported a drop-out rate of 4% in 143
patients during the first year of mepolizumab treat-
ment, mainly due to insufficient response (83%).
Ntakoula et al. (18) reported a drop-out rate of 36%
in 11 patients with a follow up of 6months. Drop-out
was due to lack of response (50%), myalgia (25%),
and personal reasons (25%). As RCTs are conducted
under rigorously controlled conditions, the drop-out
rate is expected to be higher in daily practice.
Therefore, a drop-out rate of approximately 25% 1
year from the start of mepolizumab seems reasonable.
In particular, since alternative biological treatments
became available. Benralizumab, which causes a nearly
complete elimination of airway eosinophils (19), and
reslizumab, which could have better systemic uptake
in some patients (as it is administered intravenous),
could theoretically be beneficial in some patients with
insufficient response to mepolizumab. However,
research regarding this topic is lacking. The drop-out
rate described in our study is in line with omalizumab
data, which show a drop-out rate of 7.1–19.4% and
32% in RCTs and the real world NEONet database,
respectively (20).
Bel et al. (10) described that after 20weeks of treat-
ment 14% of their patients had a 100% reduction in
mOCS use. In our cohort 27% of patients could stop
the mOCS 6months after the initiation of mepolizu-
mab, increasing up to 35.9% after 12months. The
annualized rates of exacerbations were significantly
reduced in the mepolizumab group, with our study
showing a reduction of 70%, which is higher com-
pared to the RCTs (32, 53, and 58% reduction)
(9–11). Patients in our study appear to have more
severe asthma compared to the patients included in
the RCTs, as our patients had more frequent asthma
exacerbations and used more often mOCS during the
year prior to initiation of mepolizumab treatment.
This could be due to patient selection, as patients
with a significant smoking history or considerable
comorbidity were excluded in RCTs. Patients with
more severe asthma might benefit even more from
mepolizumab therapy, which possibly explains the
greater improvement in asthma exacerbation rate and
mOCS usage in our study compared to RCTs.
We found a statistically significant and clinically
relevant improvement of ACQ 6 and 12months from
baseline. Three RCTs assessed ACQ. All reported a
statistically significant improvement of ACQ, but this
was clinically relevant in only one trial (9–11). Lung
function improved statistically significant but clinically
marginal during mepolizumab therapy. FeNO
remained high in many patients that responded to
mepolizumab therapy.
Interestingly, 9% of patients discontinued mepoli-
zumab later than 6months from the initiation of
mepolizumab. As the improvements of ACQ and lung
function are stable, and the percentage of patients
Table 3. Adverse events.a
Adverse event Number of patients (%)
Headache 7 (9.0)
Low back pain 6 (7.7)
Urinary tract infection 5 (6.4)
Spinal disc herniation 3 (3.9)
Nausea 3 (3.9)
Fatigue 3 (3.9)
Vertigo 2 (2.6)
Increase of allergic symptoms 2 (2.6)
Insomnia 2 (2.6)
aAdverse events that occurred in at least two patients are listed in
this table.
JOURNAL OF ASTHMA 5
using mOCS is even declining when comparing the
data 6 and 12months from the initiation of mepolizu-
mab, a general decrease of the efficacy of mepolizu-
mab over time is not likely. The decline in the
percentage of patients using mOCS over time is not
due to cessation of mepolizumab by mOCS users, as
the percentage of patients who used mOCS is smaller
in the group of patients that discontinued mepolizu-
mab compared to patients that continued mepolizu-
mab. Neutralizing anti-drug antibodies are probably
rare (21). The decrease in response rate 6months
from the initiation of mepolizumab could be due to
patients who show a partial response that is not con-
vincing at first, and in which the period of evaluation
is therefore extended. To better understand the long
term effectiveness of mepolizumab, a study with a fol-
low-up of multiple years is required.
No serious adverse events considered to be related
to mepolizumab were reported during our study,
which endorses mepolizumab’s favorable safety profile
(22). The most frequently reported adverse events
were headache, low back pain, and urinary tract infec-
tion, which is consistent with earlier RCTs.
In our study, patients with nonallergic eosinophilic
asthma were less likely to discontinue mepolizumab
compared to patients with allergic eosinophilic
asthma. This finding could suggest that not only
ILC2-driven eosinophilic inflammation, but also other
factors [possibly specific IgE or other TH2-cytokines
(12)] play an important role in the pathophysiology of
allergic eosinophilic asthma. However, this finding
should be interpreted with caution as this was tested
with a logistic regression analysis in a retrospective
study without correction for multiple testing, response
rate is a subjective endpoint (based on a global evalu-
ation of treatment effect by the treating pulmonolo-
gist) and, to our knowledge, no other studies tested
this hypothesis. Further research to assess this hypoth-
esis is necessary.
As this study is a retrospective cohort study, data
were not collected prospectively on standardized time
points, and patients acted as their own control,
increasing the risk of confounding: asthma is a
dynamic disease, which could result in a spontaneous
improvement of symptoms. And as our hospital is a
tertiary referral center for severe asthma, some
included patients where referred to our hospital for
mepolizumab therapy. Although conventional treat-
ment was optimized before starting mepolizumab, the
effects of other treatments could magnify the results
reported in this study. Also, there were some missing
values in the data of ACQ and lung function. It is,
however, important to assess the effectiveness of a
new treatment in real world practice, as study popula-
tions in RCTs only represent a small proportion of
the regular severe asthma population (23). Real world
cohort studies, therefore, contribute valuable comple-
mentary information to the current knowledge.
How long treatment with mepolizumab should be
continued is unknown. There are also insufficient data
to date concerning long term side effects. More
research addressing this topic is therefore needed.
In conclusion, three out of four patients were still
on mepolizumab add-on therapy one year after start-
ing mepolizumab for severe eosinophilic asthma. Our
study confirms that mepolizumab decreases the rate
of severe asthma exacerbations and hospital admis-
sions due to asthma exacerbations, improves asthma
control, reduces mOCS usage and has a favorable
safety profile in real world practice.
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Appendix
Table A1. All reported adverse events.
Adverse event Number of patients (%)
Headache 7 (9.0)
Low back pain 6 (7.7)
Urinary tract infection 5 (6.4)
Spinal disc herniation 3 (3.9)
Nausea 3 (3.9)
Fatigue 3 (3.9)
Vertigo 2 (2.6)
Increase of allergic symptoms 2 (2.6)
Insomnia 2 (2.6)
Hematoma 1 (1.3)
Syncope of unknown origin 1 (1.3)
Periorbital puffiness 1 (1.3)
Xerostomia 1 (1.3)
Lateral epicondylitis 1 (1.3)
Epistaxis 1 (1.3)
Flu like symptoms during the first 2 days following mepolizumab injection 1 (1.3)
Helicobacter pylori and Entamoeba histolytica infection 1 (1.3)
Polymorphous light eruption 1 (1.3)
Hypertension 1 (1.3)
Increase of asthma symptoms during the first couple of days following mepolizumab injection 1 (1.3)
Pruritus 1 (1.3)
Knee pain 1 (1.3)
Fever 1 (1.3)
Chronic low grade noninvasive fungal rhinosinusitis (aspergillus fumigatus) 1 (1.3)
Melanoma 1 (1.3)
Meniscus injury 1 (1.3)
Nummular dermatitis 1 (1.3)
Obstipation 1 (1.3)
Paroxysmal atrial fibrillation 1 (1.3)
Palpitations 1 (1.3)
Pharyngitis 1 (1.3)
Pain in hands and legs during the first couple of days following mepolizumab injection 1 (1.3)
Angina pectoris 1 (1.3)
Restless legs syndrome and periodic limb movement disorder 1 (1.3)
Thrombophlebitis 1 (1.3)
Urolithiasis 1 (1.3)
Forgetfulness 1 (1.3)
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